AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
47.94
+2.51 (5.52%)
At close: Oct 21, 2026, 4:00 PM EDT
47.67
-0.27 (-0.56%)
After-hours: Oct 21, 2026, 7:40 PM EDT
AnaptysBio Employees
AnaptysBio had 104 employees as of December 31, 2025. The number of employees decreased by 32 or 23.53% compared to the previous year. That makes AnaptysBio the 31,155th largest employer in the world and 3,982nd in the United States.
Employees
104
Change (1Y)
-32
Growth (1Y)
-23.53%
Revenue / Employee
$1,020,077
Profits / Employee
$2,519,154
Market Cap
1.43B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 104 | -32 | -23.53% | 104 | 0 |
| Dec 31, 2024 | 136 | 19 | 16.24% | 136 | 0 |
| Dec 31, 2023 | 117 | 21 | 21.88% | 117 | 0 |
| Dec 31, 2022 | 96 | -6 | -5.88% | 96 | 0 |
| Dec 31, 2021 | 102 | 8 | 8.51% | 102 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 828 |
| Ocular Therapeutix | 325 |
| Innoviva | 159 |
| ORIC Pharmaceuticals | 111 |
| Inhibrx Biosciences | 110 |
| Taysha Gene Therapies | 99 |
| Nanobiotix | 98 |
| Tyra Biosciences | 87 |
ANAB News
- 2 days ago - AnaptysBio notes Jemperli approved in U.S. for locally advanced rectal cancer - TheFly
- 2 days ago - Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer - GlobeNewsWire
- 21 days ago - AnaptysBio price target lowered to $60 from $70 at JPMorgan - TheFly
- 4 weeks ago - AnaptysBio price target lowered to $81 from $90 at Leerink - TheFly
- 4 weeks ago - AnaptysBio reports Q2 diluted EPS $5.11 vs. ($1.30) last year - TheFly
- 4 weeks ago - Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - AnaptysBio Earnings release: Q2 2026 - Filings
- 4 weeks ago - AnaptysBio Slides: Corporate presentation - Filings